Initiate the Phase 1 study of lead candidate A3907
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“having completed IND-enabling studies with plans for Phase 1 study initiation by end of the first quarter and topline results by the end of the year”
What we found
Evidence strength A What the grades mean
The May 2021 10-Q says the Phase 1 trial was initiated with first patient dosed in Q1 2021, meeting the end-of-Q1 deadline.
-
A Albireo Pharma, Inc. 8-K filed 2021-05-06
“The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease” ✓ confirmed on the page
-
A Albireo Pharma, Inc. 10-Q filed 2021-05-06
“We initiated a Phase 1 clinical trial, with the first patient dosed in the first quarter of 2021, we expect topline results from that trial in 2021.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 1 study of A3907
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Albireo Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C322505-024428 · Corrections policy